Clinical trial NCT05456165: Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Official title: A Randomized, Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Colonic Neoplasms
Colorectal Neoplasms
Lead sponsor: Gritstone bio, Inc.
Sponsor class: INDUSTRY
First posted: 2022-07-13
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus \[ChAd\] and self-amplifying messenger RNA \[samRNA\] vectors), in combination with checkpoint inhibitors. Antitumor activity will be based on molecular response in patients with colon cancer who have circulating tumor deoxyribonucleic acid (ctDNA) following surgical resection.

Detailed description: Tumors harboring non-synonymous deoxyribonucleic acid (DNA) mutations present peptides containing these mutations as non-self antigens in the context of human leukocyte antigens (HLAs) on the tumor cell surface. A fraction of mutated peptides results in neoantigens capable of generating T cell responses that exclusively target tumor cells. Sensitive detection of these mutations allows for the identification of neoantigens unique to each patient's tumor to be included in a personalized cancer vaccine that targets these neoantigens. This vaccine regimen uses two vaccine vectors as a heterologous prime/boost approach (GRT-C901, ChAd as prime and GRT-R902, samRNA as boost) to stimulate an immune response. This study (GRANITE-ADJUVANT) will explore the anti-tumor activity of this individualized, patient specific immunotherapy in combination with checkpoint inhibitors.

Eligibility criteria: Inclusion Criteria

For Vaccine Production Stage:

* Patients with a high-risk stage II or stage III colon cancer, including high-risk stage II colon cancer defined as meeting any of the following criteria: T4 tumors, Grade ≥3, clinical presentation with bowel obstruction or perforation, histological signs of vascular or lymphatic or perineural invasions, and \<12 nodes examined
* Patient has evidence of minimal residual disease (MRD) prior to initiating adjuvant chemotherapy (ACT) based on the presence of ctDNA
* Patient has received approximately \<6 weeks of ACT.
* Margin negative (R0) pathology on resection
* Availability of formalin fixed, paraffin embedded (FFPE) tumor specimens
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or equivalent for patients 12 to 17 years of age
* Patient has adequate organ function as defined by: peripheral white blood cell (WBC) count ≥3000/mm\^3, absolute lymphocyte count (ALC) ≥800/mm\^3, absolute neutrophils count (ANC) ≥1500/mm\^3, platelets ≥100,000/mm\^3, hemoglobin ≥9 g/dL, albumin ≥3 g/dL, calculated creatinine clearance \>50 mL/min using Cockcroft-Gault equation, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN), total serum bilirubin ≤1.5 × ULN OR direct bilirubin ≤1 × ULN, international normalized ratio (INR), prothrombin time (PT), or partial thromboplastin time (PTT) ≤1.5 × ULN, unless patient is receiving anti-coagulant therapy, in which case patients are eligible if PT and PTT are within therapeutic range of intended use of anti-coagulants, and carcinoembryonic antigen levels ≤1.5 × ULN.
* A woman of childbearing potential (WCBP) must be willing to undergo pregnancy testing and agrees to the use at least 1 highly effective contraceptive method during the study treatment period and for 5 months after last investigational study treatment

For Study Treatment Stage:

* Have a confirmed diagnosis of high-risk stage II or stage III micro-satellite stable (MSS)-colon cancer and have had their tumor surgically resected, have completed standard ACT and have no evidence of disease radiographically, and have evidence of MRD based on detection of ctDNA following ACT
* ECOG performance status of 0 to 1 or equivalent for patients 12-17 years of age
* Have adequate organ function with peripheral WBC count ≥2000/mm\^3, ALC ≥500/mm\^3, ANC ≥1000/mm\^3, platelets ≥75,000/mm\^3, hemoglobin ≥9 g/dL, albumin ≥3 g/dL, calculated creatinine clearance \>40 mL/min using Cockcroft-Gault equation, ALT and AST ≤3 × ULN, total serum bilirubin ≤1.5 × ULN OR direct bilirubin ≤1 × ULN, and INR, PT, or PTT ≤1.5 × ULN
* If a WCBP, must be willing to undergo pregnancy testing and agrees to the use at least 1 highly effective contraceptive method during the study treatment period and for 5 months after last investigational study treatment
* If male and sexually active with a WCBP, must agree to use highly effective contraception such as latex condom plus partner use of a highly effective contraceptive method during the study treatment period and for 5 months after last investigational study treatment.

Exclusion Criteria

For Vaccine Production Stage:

* Patients with micro-satellite instable (MSI)-high disease
* Patients with known tumor mutational burden (TMB) \<1 non-synonymous mutations/megabase
* Patients with known DNA Polymerase Epsilon mutations
* Known exposure to chimpanzee adenovirus (ChAd) within the prior 6 months, plan to receive a ChAd-based vaccine in the next 6 months, and/or any history or anaphylaxis in reaction to a vaccination
* Bleeding disorder or history of significant bruising or bleeding following intramuscular (IM) injections or blood draws
* Immunosuppression anticipated at time of study treatment
* Patient has received prior therapy consisting of anti-cytotoxic T lymphocyte-associated antigen (CTLA-4), anti-programmed cell death-1 receptor (PD-1), anti-programmed death ligand-1(PD-L1), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
* History of allogeneic tissue/solid organ transplant
* Active or history of autoimmune disease or immune deficiency
* History of other cancer within 2 years
* Active tuberculosis or recent (\<2 week) clinically significant infection, or evidence of active hepatitis B or hepatitis C or known history of positive test for human immunodeficiency virus (HIV) if CD4+ T-cell count is ≤200 cells/microliter.
* History of pneumonitis requiring systemic steroids for treatment (with the exception of prior resolved in-field radiation pneumonitis)
* Myocardial infarction within 3 months or prior to study treatment, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure (New York Heart Association \[NYHA\] Grade 3 and 4)
* Pregnant, planning to become pregnant, or nursing

For Study Treatment Stage

* Patient is receiving treatment with investigational products and/or other anti-cancer therapies.
* Known exposure to ChAd within the prior 6 months, plan to receive a ChAd-based vaccine in the next 6 months, and/or any history or anaphylaxis in reaction to a vaccination
* Immunosuppression from concurrent, recent (≤4 weeks) or anticipated treatment with systemic corticosteroids or other immunosuppressive medications or conditions such as hypogammaglobulinemia, or radiation exposure
* Patients who have not recovered from prior cancer therapy-induced AEs
* Any severe concurrent non-cancer disease
* Active tuberculosis or recent (\<2 weeks) clinically significant infection, evidence of active hepatitis B or hepatitis C, or known history of positive test for HIV if CD4+ T-cell count is ≤200 cells/microliter
* History of pneumonitis requiring systemic steroids for treatment
* Myocardial infarction within 6 months prior to initiating study treatment, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure (NYHA Grade 3 and 4).
* Pregnant, planning to become pregnant, or nursing

Primary outcomes:
measure: Percentage of Patients with a ≥50% Decrease from Baseline in Circulating Tumor deoxyribonucleic acid (ctDNA)
timeFrame: Baseline and up to ~24 months
measure: Incidence and Severity of Adverse Events
timeFrame: Up to ~100 days after last study treatment (Up to 62 weeks)
Secondary outcomes:
measure: Recurrence-free survival (RFS) per Investigator
timeFrame: From time of randomization until first recurrence of the same cancer, or death (Up to ~36 months)
measure: Disease-free survival (DFS) per Investigator
timeFrame: From time of randomization until first recurrence of any cancer, or death (Up to ~36 months)
measure: Overall Survival (OS)
timeFrame: From time of randomization until death due to any cause (Up to ~36 months)
measure: Conversion of Patients with ctDNA at Baseline to Undetectable ctDNA as Assessed via a Polymerase Chain Reaction (PCR)-Based Assay
timeFrame: Baseline and up to ~24 months
measure: Longest Duration of Molecular response of ctDNA Decrease from Baseline
timeFrame: Baseline and up to ~24 months
measure: Success of Vaccine Manufacture
timeFrame: Up to 28 days before Day 1 of study drug administration
measure: T-cell response using Peripheral Blood Mononuclear Cells (PBMCs)
timeFrame: Up to ~24 months
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Barbara Ann Karmanos Cancer Institute
state: Michigan
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: Cincinnati
country: United States
facility: Christ Hospital Cancer Center
state: Ohio
Study officials:
References: